Business
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned - DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it plans to file a Marketing Authorization Ap
About this update from Humacyte, Inc.
[{"type":"image","alt":"Humacyte, Inc","displaySize":"","headline":null,"caption":"Humacyte, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/trBSY4KWXHpBRzQ_5qCqbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e","width":300,"height":57}},"lazy":false},{"type":"text","content":"- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - ","length":107,"tagName":"p"},{"type":"text","content":"- Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned - ","length":111,"tagName":"p"},{"type":"text","content":"DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it plans to file a Marketing Authorization Application (MAA) with the Israel Ministry of Health for approval of the acellular tissue engineered vessel (ATEV™ or Symvess) for arterial trauma repair during the first quarter of 2026. The Company currently expects that the MAA will be evaluated by the Ministry of Health in a review period of 120 working days due to the existing Food and Drug Administration (FDA) approval of Symvess. Humacyte is working in coordination with Israeli surgeons who participated in the V005 Phase 2/3 trial of Symvess in vascular trauma and who are petitioning the Ministry of Health seeking access to the product.","length":878,"tagName":"p"},{"type":"text","content":"“Feedback from surgeons and hospitals support the need for Symvess in Israel, and we are pleased to be moving aggressively forward with our planned MAA filing this quarter,” said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. “Israel represents just our first step in the global expansion of Symvess as we expect that our FDA approval enables expedited commercialization pathways in other territories, including those in Europe and the Middle East. We plan to report further expansion plans for Symvess based on the high level of interest we are receiv...